Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Lineage Cell Therapeutics, Inc.

NYSE: LCTX · Life Sciences · 3 alerts · CIK 876343

Share price
$0.7951Close, Nov 16
Market cap
$201M
Shares outstanding
252.95MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Lineage Cell Therapeutics, Inc. filings on SEC EDGAR ↗

4:21 PM ET 10-Q
Financial Results

Lineage Cell Therapeutics Q3 2026 Results: Turns Profitable, Net Income $4.23M

For the nine months ended September 30, 2026, Lineage Cell Therapeutics reported total revenues of $4.2 million, a decrease from $7.9 million in the prior year, primarily due to lower collaboration revenues. The company significantly reduced its net loss compared to 2025, aided by a substantial $31.2 million non-cash gain from the change in fair value of warrant liabilities.

Key figure
Net income $4.23M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.